SecBot SecBot
DEFA14A ·Filed May 15, 2026

OPK

OPKO HEALTH, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-227011
Proxy solicitation materials
Actionable Insight • Neutral

Monitor proxy vote outcome on June 18, 2026, failure to approve the equity plan would force cash-based compensation, pressuring liquidity. Stockholder sentiment on the plan is the key near-term catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.13
T+0 close · May 15, 2026 · via day close
Latest settled
+23.01%
T+60 · $1.39
Vs SPY
+18.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $1.13entry
  2. T+1 · 6mo ago +1.77%α +2.42% · $1.15
  3. T+5 · 6mo ago +14.16%α +12.54% · $1.29
  4. T+20 · 5mo ago +23.01%α +21.43% · $1.39
  5. T+60 · 3mo ago +23.01%α +18.16% · $1.39

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

OPKO Health filed a DEFA14A supplement clarifying that its 2016 Equity Incentive Plan expired in February 2026, rendering 19,008,162 previously available shares no longer grantable. The board reaffirms its recommendation to approve the new 2026 Equity Incentive Plan at the June 18, 2026 annual meeting; failure to pass would halt equity grants, potentially increasing cash compensation and reducing cash for operations.

Key Financial Metrics

Vote
shareholder proposal
Meeting
2026-06-18

Key Facts

  • 2016 Equity Incentive Plan expired February 2026; 19,008,162 shares no longer available for grant.
  • Board recommends voting FOR the 2026 Equity Incentive Plan at the June 18, 2026 annual meeting.
  • If plan not approved, OPKO cannot grant new equity awards, may shift to cash compensation, reducing cash for operations.
  • Supplement clarifies prior proxy statement; no other changes to proposals.

Financial Impact

No specific dollar amounts disclosed; potential shift to cash compensation if plan fails could reduce operating cash, but magnitude unquantified.

cash_available_for_operationscompensation_expense

Risk Factors

  • Stockholders may reject the 2026 Equity Incentive Plan, halting equity grants and increasing cash compensation costs.
  • Increased cash compensation could reduce cash available for operations and R&D.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
64% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-227011
Document: 0001193125-26-227011-index-headers.html0001193125-26-227011
Document: 0001193125-26-227011-index.html0001193125-26-227011
Document: 0001193125-26-227011.txt0001193125-26-227011

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026